Search Results
Dec 08, 2025, 07:30 ET Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
Poster presentations highlight AI-driven CD histopathology grading technology; morbidity and financial burden of idiopathic multicentric CD (iMCD); severity of pediatric iMCD; and CD subtype classificationBRIDGEWATER, N.J., Dec.
More news about: Recordati
Dec 08, 2025, 07:00 ET HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
to early clinical validation highlights the potential of selective SIRPα-CD47 blockade to achieve both safety and effective immune activation in patients with limited treatment options."About HCB101: A Differentiated CD47-SIRPα BlockadeHCB101 is a 3.5th-generation, affinity-optimized
More news about: HanchorBio Inc.
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
LBL-034LBL-034 is a bispecific T-cell engager (TCE) that targets both GPRC5D and CD3, developed using the Company's proprietary LeadsBody platform. Designed with a 2:1 binding format—two sites for GPRC5D and one for CD3—LBL-034 can selectively target GPRC5D+ cancer cells, conditionally activate T cells,
More news about: Leads Biolabs
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
was 4 (range: 1-10). All patients had received at least three classes of drugs (PI, IMiD, and anti-CD38 antibody), 51.3% had received at least five classes of drugs (at least 2 PIs, 2 IMiDs, and 1 anti-CD38 antibody), 41% had previously received anti-BCMA and/or anti-GPRC5D therapies, and 76.9% were refractory
More news about: Innovent Biologics
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
Anti-CD19 panCARTM program (ORN-252) demonstrated robust B cell depletion with significant reduction in anti-dsDNA titers in humanized lupus modelAnti-BCMA panCARTM program showed robust and durable plasma cell depletion in preclinical modelsOrna
More news about: Orna Therapeutics
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, at the 2025 American Society of Hematology
More news about: Vivacta Biotechnology Co., Ltd.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
lines of therapy demonstrated stronger immune fitness versus patients with three or more prior lines of therapy, characterized by increased baseline CD4⁺ naïve T cells (a type of immune cell that has not encountered an antigen) in peripheral blood.2 Bone marrow tumor analyses from patients
More news about: Johnson & Johnson
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
BCL2 inhibitors, and CD20 antibodies. Recommended treatment regimens for newly diagnosed CLL fall into two main categories: indefinite continuous treatment with a BTK inhibitor or a fixed-duration treatment, typically lasting about a year, using a combination of a BCL2 inhibitor and CD20 antibody or BTK
More news about: American Society of Hematology
Dec 05, 2025, 12:46 ET Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
Presentation time: 5:30 PM - 5:45 PMRoom: OCCC - W414CDPacritinib in patients with high-risk myelofibrosis:
More news about: Swedish Orphan Biovitrum AB
Dec 05, 2025, 06:32 ET November in Review: 11 Top Finance Press Releases
Sealed Air to be Acquired by CD&R for $10.3 Billion"After careful review of strategic alternatives over the past year, the Board is confident that this transaction
More news about: PR Newswire
Dec 05, 2025, 06:02 ET 13 Top Press Releases from November
Sealed Air to be Acquired by CD&R for $10.3 Billion"After careful review of strategic alternatives over the past year, the Board is confident that this transaction
More news about: PR Newswire
Dec 05, 2025, 05:00 ET Run Windows on Mac (2025): Parallels Named Top Choice for macOS Users by Expert Consumers
platforms?Parallels Desktop Pro Edition includes tools for testing in Windows, Linux, and macOS environments, along with automation options for CI/CD pipelines.These answers highlight how virtualization fits into larger technical challenges faced by modern users.Industry Relevance
More news about: ExpertConsumers.org
Dec 04, 2025, 17:20 ET Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Sealed Air Buyout
whether the board members of Sealed Air Corporation (NYSE: SEE) breached their fiduciary duties in connection with the proposed sale of the company to CD&R.
More news about: Johnson Fistel, PLLP
Dec 04, 2025, 16:19 ET Best CD Rates in December 2025: CD Valet Analysis Highlights Top Yields Amid Decline
informed decisions.About CD Valet CD Valet is a digital marketplace that connects consumers with top CD rates from banks and credit unions nationwide and enables financial institutions to efficiently and cost-effectively attract retail deposits. With CD Valet, banks and credit unions
More news about: CD Valet
Dec 04, 2025, 12:20 ET Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
in the first quarter of 2026.The Phase 1 study is testing GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer
More news about: USA News Group
Dec 04, 2025, 11:39 ET Immorta Bio Reports Reduction of Tumors in Validated Models of Lung, Brain, Pancreatic, and Breast Cancers Using Anti-Aging Vaccine "SenoVax™"
tumors "hot" by boosting CD8⁺ T-cell infiltration and reducing immune-suppressive cell populations. Key findings:Statistically significant tumor growth inhibition and prolonged survival in both orthotopic and syngeneic modelsRobust CD8⁺ T-cell infiltration
More news about: Immorta Bio Inc.
Dec 04, 2025, 09:00 ET Actian Achieves Exemplary Status in ISG Data Products and Data Observability Buyers Guides
where teams can discover, share, and leverage trusted data products. Dedicated APIs automatically register and update data products within existing CI/CD pipelines, reducing manual efforts and ensuring data catalogs stay current.The ISG Data Observability Buyers Guide highlights the Actian Data
More news about: Actian
Dec 04, 2025, 08:30 ET ImmunoGenesis Receives $10.8 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Accelerate the Clinical Development of IMGS-001 for Patients with Immune-Excluded Tumors with High Unmet Need
focuses on demonstrating safety and initial clinical benefit in multiple solid tumor cohorts characterized by a high degree of immune exclusion where CD8 T cells—the immune system's soldiers—are present but locked out of the tumor. IMGS-001 has been specifically engineered to drive clinical benefit in
More news about: Immunogenesis Inc.
Dec 04, 2025, 08:00 ET MPN Research Foundation Has Two Abstracts Accepted for Presentation at ASH 2025 on Research about Treating and Living with Myeloproliferative Neoplasms
from the 2024 international assessment (Oral presentation #966) will be presented on Monday, December 8, 4:00-4:15 p.m. EST, OCCC-Room W414CD, presented by Sara Douglas, MSN, RN, OCN, Director, Patient Engagement, MPN Research Foundation.Despite therapeutic advances, patients with
More news about: MPN Research Foundation
Dec 04, 2025, 06:00 ET AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-cell malignancies
treatmentSwitchable targeting: A RevCAR receptor dimerized to the CD19/CD20 CAR enables flexible targeting of additional tumor antigens through bi- or tri-specific bridging proteins, allowing future target expansion beyond CD19/CD20.Trial Designs and ObjectivesThe phase I/II
More news about: AvenCell Therapeutics, Inc.
Dec 03, 2025, 16:56 ET Tendências para 2026: esses são os procedimentos estéticos que estarão em alta para o ano que vem
at IMCAS World Congress 2025, Paris, France. 31. Nikolis A, et al. J Drugs Dermatol. 2024 23(4):255-261.32. Humphrey CD, et al. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721 Sobre
More news about: Galderma
Dec 03, 2025, 10:30 ET Software Testing Market Worth USD 93.9 Billion by 2030 Driven by Automation and AI Integration, Says Mordor Intelligence
growing at a CAGR of 14.29%. The report notes that rapid digital transformation, the rise of cloud-native architectures, microservices, and DevOps/CI-CD practices are all increasing the demand for advanced testing solutions. Organizations are relying more on automation, AI-driven capabilities, low-code
More news about: Mordor Intelligence Private Limited
Dec 03, 2025, 08:30 ET Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting
First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated
More news about: Foresight Diagnostics, Inc.
Dec 03, 2025, 07:34 ET Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
Meeting ("WIRM") in Davos, Switzerland. These data showed progressive up-regulation of multiple exhaustion markers (PD-1, LAG-3, TIGIT, TIM-3, CD39) with repeated antigen stimulation, alongside changes in cytokine profiles in PAIS patients versus healthy controls. In simple terms, the findings suggest
More news about: Virax BioLabs Group Limited
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
clinicaltrials.gov (NCT04970901).About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The
More news about: ADC Therapeutics SA